The GAS6/AXL signaling pathway has been preclinically and clinically investigated as a therapeutic target for chemotherapy and immunotherapy in various cancer types, since the combination of AXL inhibitors with chemotherapeutic or immunotherapeutic agents can restore sensitivity and overcome therapeutic resistant tumors [41,42,43]. The gene discussed is GAS6; the disease is cancer.